---
schema_version: "secwatch.filing_event.v1"
accession: "0001640334-25-001184"
form_type: "8-K"
ticker: "ARTL"
cik: "0001621221"
company_name: "ARTELO BIOSCIENCES, INC."
filed_at: "2025-07-11T23:59:59+00:00"
generated_at: "2026-05-18T06:56:11.010746+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Artelo Biosciences completes 1-for-6 reverse split; cash falls to $2.1M with negative working capital

## Summary
- 1-for-6 reverse split effective June 13, 2025, reducing outstanding shares from 3,280,000 to ~546,667.
- Authorized common shares cut from 50M to 8,333,333; preferred authorized reduced from 416,667 to 69,444.
- Preliminary June 30, 2025 cash & equivalents ~$2.1M; working capital expected between -$1.2M and -$1.5M.
- Company restates substantial doubt about going concern and continues to report recurring operating losses.
- FY2024 net loss $9.8M (vs $9.3M in FY2023); accumulated deficit reached $50.1M at Dec 31, 2024.

## SEC filing metadata
- accession: 0001640334-25-001184
- form_type: 8-K
- ticker: ARTL
- cik: 0001621221
- company_name: ARTELO BIOSCIENCES, INC.
- filed_at: 2025-07-11T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1621221/000164033425001184/0001640334-25-001184-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1621221/000164033425001184/artl_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001640334-25-001184
- JSON: https://secwatch.observer/filing/0001640334-25-001184.json
- Plain text: https://secwatch.observer/filing/0001640334-25-001184.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.